Plasma proteome alterations by MAPK inhibitors in BRAF(V600)-mutated metastatic cutaneous melanoma()()

Approximately half of metastatic cutaneous melanomas (CM) harbor a mutation in the BRAF protooncogene, upregulating the mitogen-activated protein kinase (MAPK)-pathway. The development of inhibitors targeting the MAPK pathway (MAPKi), i.e., BRAF- and MEK-inhibitors (BRAFi and MEKi), have substantial...

Descripción completa

Detalles Bibliográficos
Autores principales: Babačić, Haris, Eriksson, Hanna, Pernemalm, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274243/
https://www.ncbi.nlm.nih.gov/pubmed/34246984
http://dx.doi.org/10.1016/j.neo.2021.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274243/
https://www.ncbi.nlm.nih.gov/pubmed/34246984
http://dx.doi.org/10.1016/j.neo.2021.06.002

Ejemplares similares